返回 Agenda
Biosimilar Interchangeability: A Global Perspective
Session Chair(s)
Nielsen Hobbs
Executive Editor
The Pink Sheet, United States
Biosimilars are the next big thing in cost-saving – that's been the promise for a while now, but why aren't we there yet? This session will discuss the successes and stumbles so far and gain insight on stimulating market access for interchangeable biosimilars.
Learning Objective : Describe the various approaches regulators and payors in different countries have used to encourage the uptake of biosimilars; Compare the success of various education efforts for biosimilars; Identify how to plan strategies to address and take advantage of the specific market conditions for biosimilars in different countries; Analyze the incentives offered to sponsors to develop interchangeable biosimilars.
Speaker(s)
Regulatory Perspective
Steinar Madsen, MD
Norwegian Medicines Agency, Norway
Medical Director
Panelist
Molly Burich, MPH
Boehringer Ingelheim Pharmaceuticals, Inc, United States
Director, Public Policy: Biosimilars and Reimbursement
Panelist
Chad Pettit, MBA
Amgen Inc., United States
Executive Director, Marketing, Global Biosimilars Commercial Lead